Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Down 69.2% in December

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totaling 14,881 shares, a drop of 69.2% from the December 15th total of 48,369 shares. Based on an average daily trading volume, of 216,984 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are sold short. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 216,984 shares, the short-interest ratio is presently 0.1 days.

Oncotelic Therapeutics Trading Up 0.1%

Shares of OTCMKTS:OTLC traded up $0.00 during midday trading on Thursday, hitting $0.07. 86,021 shares of the company’s stock were exchanged, compared to its average volume of 191,902. Oncotelic Therapeutics has a 12 month low of $0.03 and a 12 month high of $0.11. The stock has a 50 day moving average price of $0.09 and a 200-day moving average price of $0.07.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.